InvestorsHub Logo
icon url

rdfdr1

08/29/23 8:59 AM

#386578 RE: namtae #386576

Please leave! Your intent is now obvious to all. It's too late Elite is on its upward trajectory. I hope you can cover your shorts without too much pain. Nah!
icon url

jour_trader

08/29/23 9:07 AM

#386579 RE: namtae #386576

That’s a very valid question. The $5.1B figure would exclude any generics as they were just approved and IQVIA wouldn’t have any generic data included, but by how much does the total market potential decrease because of the significant shift away from branded to lower price generic? 30%, 40%? I haven’t researched this, but there may also be some volume shift to generic Vyvanse to stabilize CNS market.

On separate but similar note, Oxy will be in the same boat is it potentially shifts to generic, however, we know Elite is among first filers and may indeed be the first to file. We will know soon enough.